STOCK TITAN

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)

Aditxt, Inc. (NASDAQ: ADTX) has announced a 1-for-40 reverse stock split effective at the open of trading on October 2, 2024. The company's common stock will continue to trade under the symbol ADTX on the Nasdaq Capital Market. This decision was approved by stockholders on August 7, 2024, with the final ratio determined by the board of directors.

Key points:

  • New CUSIP number: 007025703
  • Every 40 shares will be exchanged for 1 share
  • Fractional shares will be rounded up
  • Post-split: approximately 244,667 shares outstanding

The primary goal of this reverse split is to bring Aditxt into compliance with Nasdaq's minimum bid price requirement. More information can be found in the company's definitive proxy statement filed on July 5, 2024.

Aditxt, Inc. (NASDAQ: ADTX) ha annunciato un raggruppamento azionario 1-per-40 che avrà effetto all'apertura delle contrattazioni il 2 ottobre 2024. Le azioni ordinarie della società continueranno a essere scambiate con il simbolo ADTX sul Nasdaq Capital Market. Questa decisione è stata approvata dagli azionisti il 7 agosto 2024, con il rapporto finale stabilito dal consiglio di amministrazione.

Punti chiave:

  • Nuovo numero CUSIP: 007025703
  • Ogni 40 azioni verranno scambiate per 1 azione
  • Le azioni frazionarie verranno arrotondate
  • Dopo il raggruppamento: circa 244.667 azioni in circolazione

L'obiettivo principale di questo raggruppamento è quello di portare Aditxt in conformità con il requisito del prezzo minimo di offerta del Nasdaq. Maggiori informazioni possono essere trovate nella dichiarazione di delega definitiva della società depositata il 5 luglio 2024.

Aditxt, Inc. (NASDAQ: ADTX) ha anunciado un split inverso de acciones 1 por 40 que será efectivo al inicio de la negociación el 2 de octubre de 2024. Las acciones comunes de la compañía continuarán siendo negociadas bajo el símbolo ADTX en el Nasdaq Capital Market. Esta decisión fue aprobada por los accionistas el 7 de agosto de 2024, con la razón final determinada por la junta directiva.

Puntos clave:

  • Nuevo número CUSIP: 007025703
  • Cada 40 acciones serán intercambiadas por 1 acción
  • Las acciones fraccionarias se redondearán
  • Post-split: aproximadamente 244,667 acciones en circulación

El objetivo principal de esta reducción es asegurar que Aditxt cumpla con el requisito de precio mínimo de oferta del Nasdaq. Más información se puede encontrar en la declaración de poder definitiva de la compañía presentada el 5 de julio de 2024.

Aditxt, Inc. (NASDAQ: ADTX)1대 40 비율의 액면 분할을 발표했으며, 이는 2024년 10월 2일 거래 시작 시점부터 적용됩니다. 회사의 보통주는 계속해서 Nasdaq 자본 시장에서 ADTX 기호로 거래됩니다. 이 결정은 2024년 8월 7일 주주들의 승인을 받았으며, 최종 비율은 이사회에서 결정했습니다.

주요 사항:

  • 새 CUSIP 번호: 007025703
  • 40주당 1주로 교환됩니다
  • 분할 주식은 올림 처리됩니다
  • 분할 후: 약 244,667주가 발행됩니다

이 비율 분할의 주된 목적은 Aditxt가 Nasdaq의 최소 입찰 가격 요구 사항을 준수하도록 하는 것입니다. 더 많은 정보는 2024년 7월 5일에 제출된 회사의 공식 위임장에 포함되어 있습니다.

Aditxt, Inc. (NASDAQ: ADTX) a annoncé un rachat d'actions inversé 1 pour 40 qui prendra effet à l'ouverture des marchés le 2 octobre 2024. Les actions ordinaires de la société continueront à être échangées sous le symbole ADTX sur le Nasdaq Capital Market. Cette décision a été approuvée par les actionnaires le 7 août 2024, le ratio final ayant été déterminé par le conseil d'administration.

Points clés :

  • Nouveau numéro CUSIP : 007025703
  • 40 actions seront échangées contre 1 action
  • Les actions fractionnaires seront arrondies
  • Après le rachat : environ 244 667 actions en circulation

L'objectif principal de ce rachat est de ramener Aditxt en conformité avec les exigences de prix minimal d'offre du Nasdaq. Vous pouvez trouver plus d'informations dans la déclaration de procuration définitive de la société déposée le 5 juillet 2024.

Aditxt, Inc. (NASDAQ: ADTX) hat einen 1-zu-40 Reverse-Split der Aktien bekannt gegeben, der zum Handelsbeginn am 2. Oktober 2024 wirksam wird. Die Stammaktien des Unternehmens werden weiterhin unter dem Symbol ADTX am Nasdaq Capital Market gehandelt. Diese Entscheidung wurde am 7. August 2024 von den Aktionären genehmigt, wobei das endgültige Verhältnis vom Vorstand festgelegt wurde.

Wichtige Punkte:

  • Neue CUSIP-Nummer: 007025703
  • Jede 40 Aktien wird gegen 1 Aktie eingetauscht
  • Bruchteile von Aktien werden aufgerundet
  • Nach dem Split: etwa 244.667 ausstehende Aktien

Das Hauptziel dieses Reverse-Splits ist es, Aditxt in Übereinstimmung mit den Minimalangebotspreisanforderungen von Nasdaq zu bringen. Weitere Informationen finden Sie in der definitiven Vollmachtserklärung des Unternehmens, die am 5. Juli 2024 eingereicht wurde.

Positive
  • Potential compliance with Nasdaq's minimum bid price requirement
  • Stockholder approval for the reverse stock split
Negative
  • Significant reduction in the number of outstanding shares
  • Possible indication of financial difficulties or declining stock value

Insights

The 1-for-40 reverse stock split announced by Aditxt is a significant move aimed at maintaining Nasdaq compliance. This action will reduce the number of outstanding shares from approximately 9.79 million to about 244,667, potentially boosting the stock price by a factor of 40. However, it's important to note that this doesn't change the company's underlying value or market capitalization.

The primary goal is to meet Nasdaq's $1 minimum bid price requirement, which is essential for continued listing. While this may temporarily inflate the stock price, it doesn't address fundamental business challenges or improve financial performance. Investors should be cautious, as companies resorting to reverse splits often struggle with declining share prices and may face delisting risks in the future if underlying issues aren't resolved.

The effectiveness of this strategy in maintaining long-term compliance and attracting institutional investors remains to be seen. Shareholders should closely monitor the company's financial performance and any potential dilution following the split.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, announced today that it will effect a 1-for-40 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on October 2, 2024, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the annual meeting held on August 7, 2024, with the final ratio determined by the Company’s board of directors.

As a result of the reverse stock split, the CUSIP number for the Company’s common stock will now be 007025703. As a result of the reverse stock split, every 40 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share. Immediately after the reverse stock split becomes effective, the Company will have approximately 244,667 shares of common stock issued and outstanding.

The reverse stock split is primarily intended to bring the Company into compliance with Nasdaq’s minimum bid price requirement.

Additional information concerning the reverse stock split can be found in Aditxt’s definitive proxy statement filed with the Securities and Exchange Commission on July 5, 2024, as amended.

About Aditxt, Inc.

Aditxt, Inc.® is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

For more information, www.aditxt.com.

Follow us on:
LinkedIn: https://www.linkedin.com/company/aditxt
Facebook: https://www.facebook.com/aditxtplatform/

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Aditxt, Inc.

Mary O’Brien

Mobrien@aditxt.com

516-753-9933

Source: Aditxt, Inc.

FAQ

When will Aditxt's (ADTX) 1-for-40 reverse stock split take effect?

Aditxt's (ADTX) 1-for-40 reverse stock split will take effect at the open of trading on October 2, 2024.

What is the new CUSIP number for Aditxt (ADTX) after the reverse stock split?

The new CUSIP number for Aditxt (ADTX) after the reverse stock split is 007025703.

How many shares of Aditxt (ADTX) will be outstanding after the reverse stock split?

After the reverse stock split, Aditxt (ADTX) will have approximately 244,667 shares of common stock issued and outstanding.

What is the main reason for Aditxt (ADTX) implementing the reverse stock split?

The primary reason for Aditxt (ADTX) implementing the reverse stock split is to bring the company into compliance with Nasdaq's minimum bid price requirement.

Aditxt, Inc.

NASDAQ:ADTX

ADTX Rankings

ADTX Latest News

ADTX Stock Data

2.70M
14.23M
0.01%
0.25%
10.42%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
RICHMOND